First Eagle Investment Management LLC Sells 305,943 Shares of AtriCure, Inc. $ATRC

First Eagle Investment Management LLC lessened its holdings in AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 51.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 289,343 shares of the medical device company’s stock after selling 305,943 shares during the quarter. First Eagle Investment Management LLC’s holdings in AtriCure were worth $16,261,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Teachers Retirement System of The State of Kentucky boosted its holdings in shares of AtriCure by 25.6% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 45,359 shares of the medical device company’s stock valued at $2,549,000 after acquiring an additional 9,257 shares during the last quarter. HighTower Advisors LLC increased its stake in shares of AtriCure by 109.8% in the third quarter. HighTower Advisors LLC now owns 17,812 shares of the medical device company’s stock worth $1,001,000 after acquiring an additional 9,322 shares during the period. Allworth Financial LP raised its holdings in shares of AtriCure by 54.5% during the third quarter. Allworth Financial LP now owns 2,359 shares of the medical device company’s stock worth $133,000 after purchasing an additional 832 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of AtriCure by 4.1% during the third quarter. Russell Investments Group Ltd. now owns 22,808 shares of the medical device company’s stock worth $1,282,000 after purchasing an additional 900 shares during the last quarter. Finally, Fifth Third Bancorp lifted its position in AtriCure by 488.6% during the third quarter. Fifth Third Bancorp now owns 11,543 shares of the medical device company’s stock valued at $649,000 after purchasing an additional 9,582 shares during the period. 99.11% of the stock is owned by hedge funds and other institutional investors.

AtriCure Stock Up 0.8%

AtriCure stock opened at $55.45 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 4.33 and a quick ratio of 3.29. The stock has a market capitalization of $2.82 billion, a PE ratio of 134.20 and a beta of 1.23. The business has a 50 day simple moving average of $57.63 and a 200-day simple moving average of $39.45. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $66.02.

AtriCure (NASDAQ:ATRC – Get Free Report) last announced its earnings results on Tuesday, November 3rd. The medical device company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.23. AtriCure had a return on equity of 4.01% and a net margin of 2.52%. The firm had revenue of $154.45 million for the quarter, compared to analyst estimates of $151.05 million. On average, analysts anticipate that AtriCure, Inc. will post 0.44 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Regina E. Groves sold 5,313 shares of AtriCure stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $54.22, for a total value of $288,070.86. Following the sale, the director owned 34,546 shares in the company, valued at $1,873,084.12. This trade represents a 13.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Salvatore Privitera sold 8,404 shares of the business’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $65.00, for a total transaction of $546,260.00. Following the sale, the insider directly owned 134,341 shares of the company’s stock, valued at $8,732,165. This represents a 5.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 39,026 shares of company stock worth $2,172,263. Company insiders own 4.00% of the company’s stock.

Wall Street Analysts Forecast Growth

ATRC has been the topic of several recent research reports. Stifel Nicolaus set a $70.00 price target on shares of AtriCure in a report on Thursday, November 12th. UBS Group lowered AtriCure from a “buy” rating to a “sell” rating in a research note on Wednesday, October 21st. Weiss Ratings upgraded AtriCure from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Freedom Capital cut AtriCure from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. Finally, Citigroup restated a “market outperform” rating on shares of AtriCure in a research note on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, AtriCure has an average rating of “Moderate Buy” and a consensus price target of $62.30.

Read Our Latest Report on ATRC

About AtriCure

(Free Report)

AtriCure, Inc. is a medical technology company that develops and sells products for the treatment of atrial fibrillation and other conditions addressed through cardiac surgery. Its technologies are used by surgeons and other medical professionals in hospital settings. The company’s products include surgical ablation systems designed to treat irregular heart rhythms and devices for managing the left atrial appendage, a small pouch in the heart associated with stroke risk in some patients with atrial fibrillation.

Featured Articles

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC – Free Report).

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.